$PTCT

$PTCT patients appear quite mild at baseline vs the population tested in Kuvan’s trial, comparing baseline Phe levels And not even a comparison vs Palynziq’s Well known that milder patients have better response rates (below) Would’ve been nice to have a Kuvan comparator arm in this study to judge if the drug is actually better. Likely tough commercial sell with generic Kuvan coming